Gut Microbiome Changes May Precede Alzheimer's Symptoms, Review Suggests

Alzheimer's disease has a long quiet phase. For years—sometimes decades—the brain accumulates amyloid plaques and tangles, inflammation spreads, metabolism shifts, and yet the person remains sharp. They pass cognitive tests. They remember names. They live their lives unaware that the machinery is already failing. A new review published in Nutrients suggests that during this silent preclinical window, changes may be happening in an unexpected place: the gut.

Researchers from Australia synthesized existing evidence on how diet, gut bacteria, and their chemical byproducts might intersect with the earliest biological signs of Alzheimer's. The review did not conduct new experiments or analyze fresh data, but rather assembled what is known about the gut-brain connection in the context of early disease. What emerges is a picture of potential intervention before symptoms ever appear—though the evidence remains incomplete.

The therapeutic landscape for Alzheimer's is grim. Once cognitive decline is obvious, current treatments offer only modest help. Drugs like memantine and donepezil slow decline slightly. Newer disease-modifying therapies such as lecanemab show promise but work only in select populations and provide limited benefit. Most treatments arrive too late, after substantial neurological damage has already occurred. This reality has pushed researchers to look earlier, to the preclinical stage when the brain is still changing but the person is still well. If intervention is possible, it would need to happen then.

The gut-brain axis—the two-way communication network between the central nervous system and the digestive system—appears to play a role. Bacteria in the gut produce short-chain fatty acids, or SCFAs, compounds that regulate immune cells, maintain the integrity of the gut lining, and influence inflammation throughout the body. These metabolites can reach the brain and modulate how neurons function. When the microbial community is healthy and diverse, SCFA production is robust. When it is not, these protective compounds decline.

Studies of people with established Alzheimer's disease show a consistent pattern: they have fewer bacteria from genera like Eubacterium, Roseburia, and Faecalibacterium—the main SCFA producers. At the same time, they tend to have more Proteobacteria, organisms linked to inflammatory signaling and oxidative stress. The functional capacity of their microbiota is altered too. Fermentation pathways are disrupted. Lipid and amino acid metabolism are changed. SCFA production drops. A small number of studies have found similar shifts in cognitively normal people who have amyloid pathology on brain imaging—suggesting these microbial changes may precede the cognitive symptoms by years.

Diet shapes the microbiota. The Mediterranean diet, the DASH diet (Dietary Approaches to Stop Hypertension), and the MIND diet (which combines elements of both) all emphasize plant-based foods, fish, whole grains, legumes, and low-fat dairy while limiting red meat, processed foods, added sugars, and saturated fat. People who follow these patterns show better cognitive outcomes, slower cognitive decline, and lower amyloid burden in the brain. The prudent dietary pattern—high in fruits, vegetables, whole grains, fish, and legumes—is similarly associated with improved inflammatory markers and higher abundance of SCFA-producing bacteria. The mechanism appears to be that these foods feed the right bacteria, which then produce the compounds that protect the brain.

Yet the evidence linking all three pieces together—diet, microbiome, and amyloid pathology—remains sparse and fragmented. Most studies have looked at people who already have cognitive impairment or diagnosed Alzheimer's, not at the preclinical stage. Most are cross-sectional, meaning they capture a moment in time without showing whether microbiome changes come before cognitive decline or after. Genetic sequencing of the microbiota has typically been shallow, identifying bacteria only to the genus level rather than the species level. Few studies have measured diet, microbiota composition, microbial function, SCFA levels, and brain amyloid all in the same people. The review focused primarily on SCFAs, leaving other potentially important microbial metabolites largely unexplored.

What the review makes clear is that the pieces of the puzzle exist. The gut-brain axis is real. Microbiota composition changes in Alzheimer's. Diet influences both the microbiota and cognitive outcomes. But the direct causal chain—the proof that dietary changes reshape the microbiota in ways that prevent amyloid accumulation and preserve cognition—has not yet been established in humans. Larger, longer studies of cognitively normal people with biomarker evidence of early Alzheimer's pathology will be needed to show whether intervening on diet and microbiota during the preclinical stage can actually slow or prevent the disease. Until then, the connection remains suggestive rather than proven.